Novartis AG plans to conduct a Phase II trial of the antibody drug candidate bimagrumab in obese patients with type 2 diabetes. The activin receptor type II antagonist was developed by the Novartis Institutes for Biomedical Research in collaboration with MorphoSys AG, whose HuCAL library was used to identify the antibody. (Also see "Bimagrumab 3rd Novartis drug to win FDA 'breakthrough' designation " - Scrip, 21 August, 2013.)
Novartis reported in April last year that bimagrumab failed to meet its primary endpoint in a pivotal Phase IIb/III trial...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
